Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS301984 Monotherapy and Combination in Advanced Solid Tumors
NCT06547957Phase 1Active, not recruiting
- Sponsor
- iTeos Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of EOS-984 in solid tumor (advanced stage) (2 arms), sponsored by iTeos Therapeutics. Primary endpoints: Characterization of safety and tolerability up to 4 years and Incidence and severity of AEs up to 4 years. Started Jul 2023; status: active, not recruiting.
02
Drugs
EOS-984
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06547957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547957.